Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Overexpressed nutrient transporters in solid tumors refer to a class of membrane-bound proteins, predominantly from the Solute Carrier (SLC) family, that are significantly upregulated to support the heightened metabolic requirements of cancer cells (Bhutia et al., 2016). Key members include the glucose transporter GLUT1 (SLC2A1), the amino acid transporters LAT1 (SLC7A5) and ASCT2 (SLC1A5), and the monocarboxylate transporters MCT1 (SLC16A1) and MCT4 (SLC16A3) (Ganapathy et al., 2009). These proteins facilitate the increased uptake of glucose and glutamine, as well as the export of lactate, which are essential for the Warburg effect and rapid biomass synthesis (Liberti & Locasale, 2016). By maintaining nutrient supply and pH balance, these transporters enable tumor survival, proliferation, and chemoresistance in the often-hostile tumor microenvironment (Beloribi-Djefaflia et al., 2016). Pharmacological targeting of these transporters aims to selectively starve malignant cells or induce metabolic collapse by blocking the entry of essential fuels (Zhao et al., 2011). However, a major therapeutic challenge lies in the potential for off-target toxicity, as these transporters also play critical roles in normal physiological processes, such as nutrient delivery to the brain and the activation of immune cells (Wang & Holst, 2015). For instance, GLUT1 is vital for glucose transport across the blood-brain barrier, and its systemic inhibition could lead to severe neurocognitive side effects. Similarly, LAT1 is required for the rapid expansion of T-cells during an immune response, meaning its inhibition might inadvertently cause immunosuppression.
Inhibition of substrate transport (glucose, amino acids, or lactate) across the plasma membrane, leading to metabolic exhaustion, intracellular acidification, or oxidative stress in cancer cells.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier transporters (SLC transporters) (SLC transporters).